It challenges the traditional view that cancer-associated eosinophilia is limited to hematologic malignancies and underscores the role of tumor-derived cytokines like IL-5 in driving systemic inflammation and end-organ damage. The gene discussed is IL5; the disease is Increased total eosinophil count.